Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Pre- and postconditioning the heart with hydrogen sulfide (H2S) against ischemia/reperfusion injury in vivo: a systematic review and meta-analysis.

Karwi QG, Bice JS, Baxter GF.

Basic Res Cardiol. 2017 Dec 14;113(1):6. doi: 10.1007/s00395-017-0664-8. Print 2018 Jan 8. Review.

2.

Cardioprotective effects of Viscum album L. subsp. album (European misletoe) leaf extracts in myocardial ischemia and reperfusion.

Suveren E, Baxter GF, Iskit AB, Turker AU.

J Ethnopharmacol. 2017 Sep 14;209:203-209. doi: 10.1016/j.jep.2017.07.010. Epub 2017 Jul 6.

PMID:
28689799
3.

Natriuretic peptide activation of extracellular regulated kinase 1/2 (ERK1/2) pathway by particulate guanylyl cyclases in GH3 somatolactotropes.

Jonas KC, Melrose T, Thompson IR, Baxter GF, Lipscomb VJ, Niessen SJ, Lawson C, McArdle CA, Roberson MS, McGonnell IM, Wheeler-Jones CP, Fowkes RC.

Cell Tissue Res. 2017 Sep;369(3):567-578. doi: 10.1007/s00441-017-2624-x. Epub 2017 Apr 27.

4.

AP39, a mitochondria-targeting hydrogen sulfide (H2 S) donor, protects against myocardial reperfusion injury independently of salvage kinase signalling.

Karwi QG, Bornbaum J, Boengler K, Torregrossa R, Whiteman M, Wood ME, Schulz R, Baxter GF.

Br J Pharmacol. 2017 Feb;174(4):287-301. doi: 10.1111/bph.13688. Epub 2017 Jan 24.

5.

Pharmacological postconditioning against myocardial infarction with a slow-releasing hydrogen sulfide donor, GYY4137.

Karwi QG, Whiteman M, Wood ME, Torregrossa R, Baxter GF.

Pharmacol Res. 2016 Sep;111:442-451. doi: 10.1016/j.phrs.2016.06.028. Epub 2016 Jul 1.

PMID:
27378570
6.

Nitric oxide treatments as adjuncts to reperfusion in acute myocardial infarction: a systematic review of experimental and clinical studies.

Bice JS, Jones BR, Chamberlain GR, Baxter GF.

Basic Res Cardiol. 2016 Mar;111(2):23. doi: 10.1007/s00395-016-0540-y. Epub 2016 Feb 24. Review.

7.

Postconditioning signalling in the heart: mechanisms and translatability.

Bice JS, Baxter GF.

Br J Pharmacol. 2015 Apr;172(8):1933-46. doi: 10.1111/bph.12976. Epub 2014 Dec 15. Review.

8.

Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning.

Ferdinandy P, Hausenloy DJ, Heusch G, Baxter GF, Schulz R.

Pharmacol Rev. 2014 Oct;66(4):1142-74. doi: 10.1124/pr.113.008300. Review.

PMID:
25261534
9.

Novel approaches and opportunities for cardioprotective signaling through 3',5'-cyclic guanosine monophosphate manipulation.

Bice JS, Burley DS, Baxter GF.

J Cardiovasc Pharmacol Ther. 2014 May;19(3):269-82. doi: 10.1177/1074248413518971. Epub 2014 Feb 25. Review.

PMID:
24572031
10.

Natriuretic peptides modulate ATP-sensitive K(+) channels in rat ventricular cardiomyocytes.

Burley DS, Cox CD, Zhang J, Wann KT, Baxter GF.

Basic Res Cardiol. 2014 Mar;109(2):402. doi: 10.1007/s00395-014-0402-4. Epub 2014 Jan 30.

11.

Homologous and heterologous desensitization of guanylyl cyclase-B signaling in GH3 somatolactotropes.

Thompson IR, Mirczuk SM, Smith L, Lessey AJ, Simbi B, Sunters A, Baxter GF, Lipscomb VJ, McGonnell IM, Wheeler-Jones CP, Mukherjee A, Roberson MS, McArdle CA, Fowkes RC.

Cell Tissue Res. 2014 Feb;355(2):425-36. doi: 10.1007/s00441-013-1763-y. Epub 2013 Dec 20.

12.

NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size.

Bice JS, Keim Y, Stasch JP, Baxter GF.

Cardiovasc Res. 2014 Feb 1;101(2):220-8. doi: 10.1093/cvr/cvt257. Epub 2013 Nov 20.

13.

Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology.

Ovize M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D, Hausenloy DJ, Heusch G, Vinten-Johansen J, Yellon DM, Schulz R; Working Group of Cellular Biology of Heart of European Society of Cardiology.

Cardiovasc Res. 2010 Aug 1;87(3):406-23. doi: 10.1093/cvr/cvq129. Epub 2010 May 6. Review.

PMID:
20448097
14.

Role of cGMP-PKG signaling in the protection of neonatal rat cardiac myocytes subjected to simulated ischemia/reoxygenation.

Gorbe A, Giricz Z, Szunyog A, Csont T, Burley DS, Baxter GF, Ferdinandy P.

Basic Res Cardiol. 2010 Sep;105(5):643-50. doi: 10.1007/s00395-010-0097-0. Epub 2010 Mar 28.

PMID:
20349314
15.

L-cysteine stimulates hydrogen sulfide synthesis in myocardium associated with attenuation of ischemia-reperfusion injury.

Elsey DJ, Fowkes RC, Baxter GF.

J Cardiovasc Pharmacol Ther. 2010 Mar;15(1):53-9. doi: 10.1177/1074248409357743.

PMID:
20133496
16.

Regulation of cardiovascular cell function by hydrogen sulfide (H(2)S).

Elsey DJ, Fowkes RC, Baxter GF.

Cell Biochem Funct. 2010 Mar;28(2):95-106. doi: 10.1002/cbf.1618. Review.

PMID:
20104507
17.

C-type natriuretic peptide regulation of guanosine-3',5'-cyclic monophosphate production in human endothelial cells.

Rautureau Y, Gowers I, Wheeler-Jones CP, Baxter GF.

Auton Autacoid Pharmacol. 2010 Jul;30(3):185-92. doi: 10.1111/j.1474-8673.2009.00449.x. Epub 2010 Jan 19.

PMID:
20085572
18.

Hyperlipidaemia induced by a high-cholesterol diet leads to the deterioration of guanosine-3',5'-cyclic monophosphate/protein kinase G-dependent cardioprotection in rats.

Giricz Z, Görbe A, Pipis J, Burley DS, Ferdinandy P, Baxter GF.

Br J Pharmacol. 2009 Nov;158(6):1495-502. doi: 10.1111/j.1476-5381.2009.00424.x. Epub 2009 Oct 20.

19.

Nitric oxide/cGMP signalling mediates the cardioprotective action of adrenomedullin in reperfused myocardium.

Hamid SA, Totzeck M, Drexhage C, Thompson I, Fowkes RC, Rassaf T, Baxter GF.

Basic Res Cardiol. 2010 Mar;105(2):257-66. doi: 10.1007/s00395-009-0058-7. Epub 2009 Aug 28.

PMID:
19714395
20.

Pharmacological targets revealed by myocardial postconditioning.

Burley DS, Baxter GF.

Curr Opin Pharmacol. 2009 Apr;9(2):177-88. doi: 10.1016/j.coph.2008.11.009. Epub 2008 Dec 26. Review.

PMID:
19109069
21.

Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning.

Ferdinandy P, Schulz R, Baxter GF.

Pharmacol Rev. 2007 Dec;59(4):418-58. Epub 2007 Nov 29. Review.

PMID:
18048761
22.

Apelin reduces myocardial reperfusion injury independently of PI3K/Akt and P70S6 kinase.

Kleinz MJ, Baxter GF.

Regul Pept. 2008 Feb 7;146(1-3):271-7. Epub 2007 Oct 22.

PMID:
18022257
23.

Reperfusion and calculated RISKs: pharmacological postconditioning of human myocardium.

Baxter GF, Burley DS.

Br J Pharmacol. 2008 Jan;153(1):1-3. Epub 2007 Oct 22.

24.

B-type natriuretic peptide at early reperfusion limits infarct size in the rat isolated heart.

Burley DS, Baxter GF.

Basic Res Cardiol. 2007 Nov;102(6):529-41. Epub 2007 Sep 26.

PMID:
17896117
25.

Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling.

Burley DS, Ferdinandy P, Baxter GF.

Br J Pharmacol. 2007 Nov;152(6):855-69. Epub 2007 Aug 13. Review.

26.

Ischemic preconditioning is lost in aging hypertensive rat heart: independent effects of aging and longstanding hypertension.

Ebrahim Z, Yellon DM, Baxter GF.

Exp Gerontol. 2007 Aug;42(8):807-14. Epub 2007 Apr 24.

PMID:
17532161
27.

Cardioprotective actions of peptide hormones in myocardial ischemia.

Burley DS, Hamid SA, Baxter GF.

Heart Fail Rev. 2007 Dec;12(3-4):279-91. Review.

PMID:
17516166
28.

Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium.

Hamid SA, Bower HS, Baxter GF.

Am J Physiol Heart Circ Physiol. 2007 Jun;292(6):H2598-606. Epub 2007 Jan 12.

29.
30.

A critical cytoprotective role of endogenous adrenomedullin in acute myocardial infarction.

Hamid SA, Baxter GF.

J Mol Cell Cardiol. 2006 Aug;41(2):360-3. Epub 2006 Jul 13.

PMID:
16842816
31.

Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin.

Roy D, Quiles J, Gaze DC, Collinson P, Kaski JC, Baxter GF.

Heart. 2006 Jan;92(1):113-4. No abstract available.

32.

Exogenous hydrogen sulfide (H2S) protects against regional myocardial ischemia-reperfusion injury--Evidence for a role of K ATP channels.

Johansen D, Ytrehus K, Baxter GF.

Basic Res Cardiol. 2006 Jan;101(1):53-60. Epub 2005 Nov 21.

PMID:
16328106
33.

Representational difference analysis of cDNA identifies novel genes expressed following preconditioning of the heart.

Fauchon MA, Pell TJ, Baxter GF, Yellon DM, Latchman DS, Hubank MF, Mayne LV.

Exp Mol Med. 2005 Aug 31;37(4):311-22.

PMID:
16155408
34.

Adrenomedullin limits reperfusion injury in experimental myocardial infarction.

Hamid SA, Baxter GF.

Basic Res Cardiol. 2005 Sep;100(5):387-96. Epub 2005 Jul 15.

PMID:
16010601
35.

Adrenomedullin: regulator of systemic and cardiac homeostasis in acute myocardial infarction.

Hamid SA, Baxter GF.

Pharmacol Ther. 2005 Feb;105(2):95-112. Review.

PMID:
15670621
36.

Acute actions of natriuretic peptides in coronary vasculature and ischaemic myocardium.

Rautureau Y, Baxter GF.

Curr Pharm Des. 2004;10(20):2477-82. Review.

PMID:
15320757
37.

Effect of radiofrequency catheter ablation on the biochemical marker ischemia modified albumin.

Roy D, Quiles J, Sinha M, Floros D, Gaze D, Collinson P, Baxter GF, Kaski JC.

Am J Cardiol. 2004 Jul 15;94(2):234-6.

PMID:
15246911
38.
39.

Limitation of myocardial reperfusion injury by AMP579, an adenosine A1/A2A receptor agonist: role of A2A receptor and Erk1/2.

Kis A, Baxter GF, Yellon DM.

Cardiovasc Drugs Ther. 2003 Sep-Nov;17(5-6):415-25.

PMID:
15107596
40.

Natriuretic peptides and myocardial ischaemia.

Baxter GF.

Basic Res Cardiol. 2004 Mar;99(2):90-3. Epub 2004 Jan 23. Review.

PMID:
14963667
41.

The natriuretic peptides.

Baxter GF.

Basic Res Cardiol. 2004 Mar;99(2):71-5. Epub 2004 Jan 23. Review.

PMID:
14963664
42.

Autocrine and paracrine actions of natriuretic peptides in the heart.

D'Souza SP, Davis M, Baxter GF.

Pharmacol Ther. 2004 Feb;101(2):113-29. Review.

PMID:
14761702
43.
44.

B Type natriuretic peptide: a good omen in myocardial ischaemia?

D'Souza SP, Baxter GF.

Heart. 2003 Jul;89(7):707-9. No abstract available.

45.
46.

Role of nuclear factor-kappa B activation in acute ischaemia-reperfusion injury in myocardium.

Kis A, Yellon DM, Baxter GF.

Br J Pharmacol. 2003 Mar;138(5):894-900.

47.

B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening.

D'Souza SP, Yellon DM, Martin C, Schulz R, Heusch G, Onody A, Ferdinandy P, Baxter GF.

Am J Physiol Heart Circ Physiol. 2003 May;284(5):H1592-600. Epub 2003 Jan 9.

48.

Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning?

Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM.

Cardiovasc Res. 2002 Aug 15;55(3):534-43.

PMID:
12160950
49.

Role of adenosine in delayed preconditioning of myocardium.

Baxter GF.

Cardiovasc Res. 2002 Aug 15;55(3):483-94. Review.

PMID:
12160945
50.

The neutrophil as a mediator of myocardial ischemia-reperfusion injury: time to move on.

Baxter GF.

Basic Res Cardiol. 2002 Jul;97(4):268-75. Review.

PMID:
12111036

Supplemental Content

Loading ...
Support Center